Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2009

View Archived Issues

Inhibitors of apoptosis inhibitor proteins (IAP) disclosed at Genentech for cancer

Thyroid-stimulating hormone receptor agonists created at NIH

N. lactamica outer membrane vesicle meningococcal vaccine tested in phase I study

Novel IKK2-inhibiting compounds tested for antiarthritic potential at GlaxoSmithKline

Pure androgen receptor antagonist CH-4933468 developed at Chugai

Inhibitors of CDK1, CDK5 and GSK-3 with anticancer activity developed at CNRS

Novel compounds for menopausal syndrome and oral contraception claimed by Bayer Schering Pharma

Wellstat Therapeutics claims compounds for treating type 2 diabetes

Lilly describes glucocorticoid receptor agonists for rheumatoid arthritis

Cannabinoid receptor ligands created for pain therapy at Purdue Pharma

Wyeth presents novel benzofuran analogues designed to inhibit NE reuptake

Cephalon details discovery and testing of c-Met inhibitors for cancer

Taspoglutide improves glycemic control in patients unresponsive to metformin

AstraZeneca Canada files NDS for FluMist vaccine

AMG-386 active and well tolerated in patients with advanced solid tumors

Health Canada approves Rituxan for treatment of CLL

Novel aromatase inhibitors claimed for cancer

The NIH awards grant to Advaxis for dual antigen vaccine

Yakult's Elplat approved for postoperative adjuvant chemotherapy of colon cancer

FDA approves two NDAs for Lundbeck's Sabril for IS and CPS

Biovail acquires U.S. and Canadian rights to develop and commercialize Santhera's fipamezole

Potential benefits for Avastin in second-line setting

Novartis' Xolair approved for severe persistent allergic asthma in children aged 6 to 11

FDA accepts for filing Cell Therapeutics' NDA for pixantrone in NHL

UCB and Novartis sign licensing agreement for cardiovascular, diabetes drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...